Waltham, Massachusetts Friday, November 15, 2024, 15:00 Hrs [IST] ...

reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

While the etiology of IPF is unknown, preventing injury/damage to the epithelium barrier and consequent expansion of fibroblast and extracellular matrix is an appropriate step in the right direction.

The study examined one of these brakes, called MKP1—which the team found was expressed at lower levels in fibroblasts from ...

Aileron Therapeutics (ALRN) announced positive topline data from Cohort 2 of its Phase 1b clinical trial evaluating the safety and tolerability ...

These cells, in turn, express a receptor on their surface that promotes interactions with fibroblast cells on the outside of the lungs, leading to excess collagen production that can spur lung ...

Black patients with IPF are hospitalized younger but have better inpatient survival than White patients, who are more likely to receive antifibrotic medications. Racial disparities in lung cancer ...

Core Director: Rui-Ming Liu, Ph.D. Idiopathic pulmonary fibrosis (IPF) is a most enigmatic fatal lung disorder. Although significant progress has been made in our understanding of IPF pathogenesis, ...